Vemurafenib in refractory langerhans histiocytosis

1Emile JF, Abla Q, Fraitag S, Hornes A, Haroches J, Donandieu J, Requena-Caballero L, Jordan MB, Abdel-Wahab O, Allen CE, Charlotte F, Diamond EL, Egeler RM, Fischer A, Herrera JG, Hentler JI, Janku F, Merad M, Picarsic J, Rodriguez-Galindo C, Rollins BJ, Tazi A, Vaddallo R, Weiss LM for the Histiocyte Society. Revised classification ofhistiocytoses and neoplasms of the macrophagr-dendritic cell lineages. Blood 2016 Jun 2;127(22):2672-2681.Emile JF Abla Q Fraitag S Hornes A Haroches J Donandieu J Requena-Caballero L Jordan MB Abdel-Wahab O Allen CE Charlotte F Diamond EL Egeler RM Fischer A Herrera JG Hentler JI Janku F Merad M Picarsic J Rodriguez-Galindo C Rollins BJ Tazi A Vaddallo R Weiss LM for the Histiocyte Society. Revised classification ofhistiocytoses and neoplasms of the macrophagr-dendritic cell lineages Blood 2016 Jun 2127222672 268110.1182/blood-2016-01-690636516100726966089Search in Google Scholar

2Haupt R, Minkov M, Astigarraga I, Schäfer E, Nanduri V, Jubran R, Egeler RM, Janka G, Micic D, Rodriguez-Galindo C, Van Gool S, Visser J, Weitzman S, Donadieu J; Euro Histio Network. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013 Feb;60(2):175-178.Haupt R Minkov M Astigarraga I Schäfer E Nanduri V Jubran R Egeler RM Janka G Micic D Rodriguez-Galindo C Van Gool S Visser J Weitzman S Donadieu J; Euro Histio Network. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years Pediatr Blood Cancer 2013 Feb602175 17810.1002/pbc.24367455704223109216Search in Google Scholar

3Adam E, Jubran R, Weitzman S. Epidemiology and clinical manifestation of Langerhans cell histiocytosis in children. W: Histiocytic disorders. Abla O, Janka G (red.) 1^st ed. Springer, 2018.Adam E Jubran R Weitzman S Epidemiology and clinical manifestation of Langerhans cell histiocytosis in children. W: Histiocytic disorders. Abla O, Janka G (red.) 1^st ed Springer 201810.1007/978-3-319-59632-7_3Search in Google Scholar

4Raciborska A, Rogowska E, Słowińska M. Pacjent z Histiocytozą z komórek Langerhansa. Co ważnego dla Pediatry. Pediatr Dyplom. 2018,3:75-84.Raciborska A Rogowska E Słowińska M Pacjent z Histiocytozą z komórek Langerhansa Co ważnego dla Pediatry. Pediatr Dyplom 2018375 84Search in Google Scholar

5Heisig A, Sörensen J, Zimmermann SY, Schöning S, Schwabe D, Kvasnicka HM, Schwentner R, Hutter C, Lehrnbecher T. Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature. Oncotarget. 2018 Apr 24;9(31):22236-22240.Heisig A Sörensen J Zimmermann SY Schöning S Schwabe D Kvasnicka HM Schwentner R Hutter C Lehrnbecher T Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature Oncotarget 2018 Apr 2493122236 2224010.18632/oncotarget.25277595514529774135Search in Google Scholar

6Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010 Sep 16;116(11):1919-1923.Badalian-Very G Vergilio JA Degar BA MacConaill LE Brandner B Calicchio ML Kuo FC Ligon AH Stevenson KE Kehoe SM Garraway LA Hahn WC Meyerson M Fleming MD Rollins BJ. Recurrent BRAF mutations in Langerhans cell histiocytosis Blood 2010 Sep 16116111919 192310.1182/blood-2010-04-279083317398720519626Search in Google Scholar

7Tran G, Huynh TN, Paller AS. Langerhans cell histiocytosia: a neoplastic disorder driven by Ras-ERK pathway mutations. J Am Acad Dermatol. 2018 Mar;78(3):579-590.Tran G Huynh TN Paller AS Langerhans cell histiocytosia: a neoplastic disorder driven by Ras-ERK pathway mutations J Am Acad Dermatol 2018 Mar783579 59010.1016/j.jaad.2017.09.02229107340Search in Google Scholar

8Rollins BJ. Biology and genomics of LCH and related disorders. W: Histiocytic disorders. Abla O, Janka G (red.) 1^st ed. Springer, 2018.Rollins BJ Biology and genomics of LCH and related disorders. W: Histiocytic disorders. Abla O, Janka G (red.) 1^st ed Springer 201810.1007/978-3-319-59632-7_2Search in Google Scholar

9Rizzo FM, Cives M, Simone V, Silvestris F. New insights into the molecular pathogenesis of langerhans cell histiocytosis. Oncologist. 2014 Feb;19(2):151-163.Rizzo FM Cives M Simone V Silvestris F New insights into the molecular pathogenesis of langerhans cell histiocytosis Oncologist 2014 Feb192151 16310.1634/theoncologist.2013-0341392678924436311Search in Google Scholar

10Hutter C, Minkov M. Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies. Immunotargets Ther. 2016 Oct 12;5:81-91.Hutter C Minkov M Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies Immunotargets Ther 2016 Oct 12581 9110.2147/ITT.S91058506685027785447Search in Google Scholar

11Haroche J, Cohen-Aubart F, Emile JF, Donadieu J, Amoura Z. Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis. J Am Acad Dermatol. 2015 Jul; 73(1):e29-30. Haroche J Cohen-Aubart F Emile JF Donadieu J Amoura Z Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis J Am Acad Dermatol 2015 Jul 731e29 3010.1016/j.jaad.2014.10.04526089069Search in Google Scholar

12Héritier S, Jehanne M, Leverger G, Emile JF, Alvarez JC, Haroche J, Donadieu J. Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis. JAMA Oncol. 2015 Sep; 1(6):836-838.Héritier S Jehanne M Leverger G Emile JF Alvarez JC Haroche J Donadieu J. Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis JAMA Oncol 2015 Sep 16836 83810.1001/jamaoncol.2015.073626180941Search in Google Scholar